Search
Dinshaw J. Patel, a Member in Sloan Kettering Institute's Structural Biology Program and incumbent of the Abby Rockefeller Mauzé Chair in Experimental Therapeutics, was elected to the National Academy of Sciences at its 146th annual meeting in April.
MSK researchers discover a possible reason why people with kidney cancer respond better to treatments such as immunotherapy if they are obese.
MSK 斯隆的研究人员发现了肾癌患者在肥胖的情况下对免疫疗法等治疗反应更好的一个可能原因。MSK 斯隆的研究人员发现了肾癌患者在肥胖的情况下对免疫疗法等治疗反应更好的一个可能原因。
African American patients with colorectal cancer are less likely to have tumors that respond well to newer treatments such as targeted therapy and immunotherapy.
It can be hard to understand all the various radiation therapy options for prostate cancer. Here, we explain.
Puede ser difícil comprender las diversas opciones de radioterapia utilizadas para tratar el cáncer de próstata. Aquí las explicamos.
Scientists at Memorial Sloan Kettering have pieced together the biochemical mechanism by which the tuberculosis bacterium sneaks past our immune defenses.
Read about a powerful research model developed by MSK researchers to learn how the most common type of prostate cancer changes into a deadly form.
MSK physician-scientist Prasad Adusumilli is focused on developing more-effective immunotherapy approaches for treating tumors in the chest.
During the June 8 edition of “MSK Science Spotlight,” radiochemist Jason Lewis, PhD, will share his perspectives on “Defying the Limitations of Antibodies for Imaging and Endoradiotherapy.”